Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

doi:10.1158/1078-0432.CCR-15-0584

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2015

Frenel Jean Sebastien, Carreira Suzanne, Goodall Jane, Roda Desam, Perez-Lopez Raquel, Tunariu Nina, Riisnaes Ruth, Miranda Susana, Figueiredo Ines, Nava-Rodrigues Daniel, Smith Alan, Leux Christophe, Garcia-Murillas Isaac, Ferraldeschi Roberta, Lorente David, Mateo Joaquin, Ong Michael, Yap Timothy A, Banerji Udai, Gasi Tandefelt Delila, Turner Nick, Attard Gerhardt, de Bono Johann S

Abstract excerpt

PURPOSE: We evaluated whether next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) could be used for patient selection and as a tumor clone response biomarker in patients with advanced cancers participating in early-phase clinical trials of targeted drugs. EXPERIMENTAL DESIGN: Pl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Complementary

Share to DNA, Neoplasm

Share to Neoplastic Cells, Circulating

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to ras Proteins

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26085511
DOI: 10.1158/1078-0432.CCR-15-0584
PMCID: PMC4580992

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26085511-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.PMID 26085511Read ↗

Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.Semantic proximity Read ↗

Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients.Semantic proximity Read ↗

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.Semantic proximity Read ↗

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.Semantic proximity Read ↗

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.Semantic proximity Read ↗

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorSemantic proximity Read ↗

Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.Semantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutated <i>KDR</i> /VEGFR2 receptors as modulators of anti-angiogenic therapiesSemantic proximity Read ↗

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.